Illuminating clinical blind spots
Dr David Cardoso CBO
Sam Van Bohemen CEO & CTO
Get in Contact
T: 0435 045 054
What (and whose) problem is your company trying to solve?
CT scans are used to diagnose stroke. They provide imaging snapshots and due to radiation exposure are only performed every 24 hours. In the first 24 hours, patients will receive treatment and are at risk of having a secondary stroke. However, there is currently no way to continuously monitor cerebral blood flow (CBF) and brain activity, which are key indicators in stroke. Standard care relies upon follow up CT scans and nurses talking to patients, which is subjective.
We are developing a wearable device that utilises a proprietary multi-modal system to provide continuous monitoring of CBF and brain activity. This will enable treatment monitoring and the detection of secondary strokes. Leading to faster detection, intervention and improved patient outcome. This will also reduce the number of CT scans required.
Sam Van Bohemen
Co-founder, CEO & CTO, Nuroflux
Would you like to call out a mentor who has helped your company? Tell us a little about them.
Dr Philip Boughton, one of my PhD supervisors has been instrumental in the creation of nuroflux. Philip has been active in the medtech industry for over 20 years. He has a passion for developing innovative healthcare solutions. I am very grateful for Philip’s continued support as nuroflux continues to grow.